FDA Dispute Resolution Rules May Not Supplant Informal Appeals - Morrison
Industry continues to exercise informal appeals rather than official dispute resolution procedures to address disagreements with FDA, Center for Drug Evaluation & Research Ombudsman Jim Morrison said.
You may also be interested in...
FDA must present a compelling argument for denial of a sponsor's request for an advisory committee review of an unresolved scientific dispute with the agency, the Pharmaceutical Research & Manufacturers of America said in comments on FDA's draft guidance for formal dispute resolution.
Appeals for dispute resolution between a product sponsor and FDA, including requests for advisory committees to hear disputes, will be approved or denied by the agency within 30 days for user fee products, a March 19 draft guidance indicates.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011